The knock-down of CTLA-4, albeit partial, was evidently sufficient to trigger enhancement of 19z1-CD80+ T cells’ anti-tumor properties, although not modifying those of 19-28z+ T cells. The gene discussed is CTLA4; the disease is neoplasm.